PT2399

Item no.	TMO-T12675L-25mg
Manufacturer	TargetMol
CASRN	1672662-14-4
Amount	25 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	98.80%
Citations	Wehn PM, et al. Design and Activity of Specific Hypoxia-Inducible Factor-2alpha (HIF-2alpha) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem. 2018 Nov 8;61(21):9691-9721.
Smiles	O[C@H]1c2c(CC1(F)F)c(Oc1cc(F)cc(c1)C#N)ccc2S(=O)(=O)C(F)F
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	1672662-14-4,HIF
Shipping Condition	Cool pack
Available
Manufacturer - Targets	HIF/HIF Prolyl-Hydroxylase\|\|\|HIF
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	419.32
Description	PT2399 is a first-in-class, orally available, small molecule inhibitor of HIF-2 that selectively disrupts the heterodimerization of HIF-2α with HIF-1β. PT2399 displays potent antitumor activity in vivo
Pathways	Angiogenesis\|\|\|Metabolism\|\|\|Chromatin/Epigenetic

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T12675L-25mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question